Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do in Florida

If you’re a psychiatrist or psychiatric nurse practitioner, you’ve probably noticed the explosion of interest in weight-loss medications—particularly GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide. Maybe you’ve had patients ask if you can prescribe them. Maybe you’ve wondered if adding weight management to your practice makes sense, both clinically and financially.

Here’s the reality: Yes, psychiatrists and many PMHNPs can legally prescribe weight-loss medications, but the answer isn’t quite that simple. Your ability to do so depends on your license type, your state’s regulations, whether you’re practicing via telehealth, and—critically—whether you have the training and competence to manage metabolic health alongside mental health.

This guide cuts through the confusion. We’ll cover the legal scope of practice for MDs versus NPs, state-by-state prescribing rules, telehealth restrictions, reimbursement realities, and the clinical rationale for psychiatrists entering this space. Whether you’re considering adding weight management to your existing practice or evaluating a telehealth platform that offers it, you’ll know exactly where you stand.

Why Psychiatrists Are Prescribing Weight-Loss Medications

The Metabolic-Psychiatric Connection

Traditionally, psychiatrists stick to psychotropics. But the lines are blurring—and for good reason. Many psychiatric patients struggle with obesity, often caused by the medications we prescribe. Second-generation antipsychotics, mood stabilizers, even some antidepressants can trigger significant weight gain. When a patient gains 40 pounds on olanzapine, their physical and mental health both suffer.

GLP-1 receptor agonists were originally diabetes drugs, but they’ve proven extraordinarily effective for weight loss—so much so that the FDA approved dedicated formulations (Wegovy, Saxenda) for obesity treatment. These medications don’t just help patients lose weight; emerging evidence suggests they may offer psychiatric benefits: reduced binge-eating impulses, decreased substance cravings, and potentially improved mood independent of weight loss.

Dr. Elliott Lewis, a psychiatrist board-certified in obesity medicine, puts it bluntly: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ He argues that managing a patient’s weight—especially when psychiatric medications contributed to it—isn’t ‘scope creep.’ It’s comprehensive care.

Is This Really Within a Psychiatrist’s Scope?

The concern is legitimate: weight management traditionally falls to primary care or endocrinology. But scope of practice isn’t defined by specialty silos—it’s defined by competence. If you gain the necessary knowledge (through CME, mentorship, or formal training like the American Board of Obesity Medicine certification), prescribing GLP-1s is a reasonable extension of psychiatric practice.

Psychiatrists already monitor metabolic parameters (glucose, lipids, weight) for patients on psychiatric drugs. Many already prescribe medications that affect metabolism—metformin for antipsychotic-induced weight gain, for example. Adding a GLP-1 to address medication-induced obesity or comorbid metabolic syndrome isn’t a radical departure; it’s treating the whole patient.

The Training Question

That said, you can’t just wing it. Best practice involves additional education in obesity medicine—understanding the pathophysiology of weight regulation, contraindications for weight-loss drugs, monitoring protocols, and nutritional counseling basics. Many psychiatrists are pursuing the ABOM certification (American Board of Obesity Medicine), which requires ~60 hours of obesity-focused CME and passing an exam. ABOM explicitly welcomes psychiatrists, and dual certification signals to patients, employers, and regulators that you’re qualified to manage both conditions.

Even without formal certification, structured CME on GLP-1 pharmacology, patient selection criteria, and safety monitoring is essential before you write your first prescription.

Safety Profile: Are GLP-1s Risky for Psychiatric Patients?

A major concern for mental health providers: do GLP-1s cause depression or suicidality? High-profile media reports suggested a link, but the data is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increased risk of depression or suicidal ideation with GLP-1 medications versus placebo. Regulatory agencies (FDA and EMA) reviewed the evidence and found no causal relationship.

In fact, clinical trial data show GLP-1-treated groups had slightly lower rates of depressive symptoms compared to controls in landmark trials like the STEP studies. Quality-of-life scores improved, likely driven by weight loss and metabolic benefits but possibly also through direct central nervous system effects (GLP-1 receptors exist in mood-regulating brain regions).

Bottom line: with appropriate screening and monitoring, GLP-1s are safe for psychiatric populations. You should still assess for eating disorders, document any history of pancreatitis or thyroid cancer (relative contraindications), and follow up regularly—but psychiatric diagnosis alone isn’t a contraindication.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Who Can Prescribe What?

Psychiatrists (MD/DO): Full Prescriptive Authority

If you’re a licensed physician—psychiatrist, family doc, anyone with an MD or DO—you have broad prescriptive authority in all 50 states. That includes:

• Non-controlled weight-loss medications: GLP-1 agonists (semaglutide, liraglutide, tirzepatide), orlistat, naltrexone-bupropion combinations—all fair game.
• Controlled substances: Schedule IV drugs like phentermine (the most commonly prescribed appetite suppressant) are within your scope, provided you follow state-specific rules (some states ban certain uses; more on that below).

No additional certification is legally required to prescribe obesity drugs—your DEA registration and state medical license cover it. However, state medical boards expect you to practice within your competence. If you prescribe outside your training without proper education, you risk discipline for negligence or practicing below the standard of care.

Some states impose specific protocols for weight-loss prescribing (Florida and New Jersey have detailed regulations), but these apply equally to all physicians. As an MD, you have the authority; the question is whether you have the expertise.

Psychiatric Mental Health Nurse Practitioners (PMHNPs): It Depends

For nurse practitioners, prescribing authority varies dramatically by state. The key variables:

1. Full Practice Authority (FPA) vs. Collaborative Practice: Roughly half of U.S. states grant NPs full practice authority—meaning you can evaluate, diagnose, and prescribe independently without physician oversight. The other half require some form of physician collaboration or supervision.

2. Specialty Scope: You’re trained as a psychiatric NP. Does prescribing weight-loss medications fall within your population focus? Technically, scope is defined by competency, not diagnosis. If you’re treating a psychiatric patient whose weight issues intersect with their mental health (e.g., medication-induced obesity, binge eating disorder), it’s arguably within scope. If you’re running a standalone weight-loss clinic for the general public without psychiatric involvement, regulators might question your qualification.

3. Controlled Substance Authority: Many weight-loss regimens include phentermine (Schedule IV). Some states allow NPs to prescribe controlled substances independently (if they have FPA), while others require physician co-signature or delegation agreements.

State-by-State Snapshot for NPs:

Key Takeaway for NPs: If you’re in a full-practice state (or meet the experience threshold in states like IL or NY), you can prescribe GLP-1s and other weight-loss medications independently—provided you’ve documented the training/competence to do so. If you’re in a collaborative state, you’ll need an MD partner who’s willing to oversee this aspect of your practice.

Practical Reality: Even in FPA States, MD Involvement Helps

Here’s something many NPs discover the hard way: even in independent-practice states, insurers and pharmacies sometimes push back on NP-signed prescriptions for expensive or controlled medications. A Washington-based NP (full practice state) reports that certain insurance prior authorizations for Wegovy require an MD’s name, and some compounding pharmacies refuse to fill semaglutide scripts from NPs without physician co-signature—even though state law doesn’t require it.

This isn’t a legal barrier, but it’s a business barrier. Many telehealth platforms solve this by having a medical director (MD/DO) in each state to co-sign or at least be available for consultation, smoothing the insurance and pharmacy friction. If you’re an NP building an independent practice, factor this in: you may need an MD collaborator not for legal compliance, but for operational ease.

State-Specific Prescribing Rules: The Details That Matter

Weight-loss prescribing isn’t just about having a license—states impose additional clinical and documentation standards. Ignoring these can lead to board complaints or worse.

Florida: Strict Standards and No Telehealth for Controlled Appetite Suppressants

Florida is one of the most regulated states for weight-loss treatment. Here’s what you must do:

• Patient Qualification: Document BMI ≥30 (or ≥27 with comorbidity) before prescribing any anti-obesity drug. State rule explicitly requires this (Fla. Admin. Code 64B15-14.004).
• Comprehensive Evaluation: Before the first prescription, you must conduct (or delegate to an APRN/PA) a full history and physical exam, including labs to rule out secondary causes of obesity (thyroid, etc.). This doesn’t have to be in-person by statute, but the exam must be thorough enough to meet the standard of care.
• Informed Consent: Written consent documenting risks, benefits, and alternatives is mandatory.
• Follow-Up: Patients must be seen (video visits count) at least every 3 months while on weight-loss medication. Missing this schedule is a common cause of disciplinary action.
• Consumer Bill of Rights: You must give patients Florida’s official ‘Weight-Loss Consumer Bill of Rights’ brochure at the start of treatment.

The Telehealth Trap: Florida law prohibits prescribing controlled substances via telehealth except for psychiatric disorders, inpatient/hospice care, or acute pain treatment. Weight loss is not an exception. That means you cannot prescribe phentermine (Schedule IV) via telehealth to a Florida patient under current law. GLP-1s (semaglutide, etc.) are non-controlled, so those are allowed via telehealth—but you still must meet all the above documentation requirements.

Bottom Line for Florida: If you’re treating Florida patients via telehealth, stick to non-controlled weight-loss meds (GLP-1s, orlistat) and ensure you have a FL-licensed physician as medical director if you’re an NP.

Texas: Physician Oversight Required, Monthly Collaboration

Texas doesn’t allow independent NP practice. All NPs must have a Prescriptive Authority Agreement (PAA) with a Texas-licensed physician that explicitly covers weight-loss medications.

• PAA Requirements: The agreement must detail which drugs the NP can prescribe (including Schedule IV if applicable), communication/consultation protocols, and quality assurance (chart review, monthly face-to-face meetings between NP and MD).
• Physician Ratio: One Texas physician can supervise up to 7 NP/PA prescribers outside a hospital.
• Telehealth: Texas allows telehealth prescribing (including controlled substances during the federal DEA waiver period) as long as you establish a proper patient-practitioner relationship via video/audio. You must check the Texas PMP for controlled substance prescriptions.
• No Schedule II for Weight Loss: Texas law prohibits using Schedule II stimulants (amphetamines) for weight loss. Phentermine (Schedule IV) is allowed.

Bottom Line for Texas: If you’re a psychiatrist, you can prescribe weight-loss meds (including phentermine) via telehealth with proper documentation. If you’re an NP, you need a Texas MD collaborator with a signed PAA that covers these medications.

California: Transitioning to NP Independence, But CPOM Remains

California is phasing in NP independence via Assembly Bill 890. As of 2023, experienced NPs can practice in certain settings without standardized procedures; by January 2026, qualified NPs (those who completed 3 years/4,600 hours of transition practice) can open independent practices.

However, California’s Corporate Practice of Medicine doctrine still requires physician ownership or oversight of medical practices. Even an independent NP in 2026 may need to operate within a physician-owned entity or professional corporation for regulatory compliance.

• Prescribing: Psychiatrists have full authority. NPs currently need physician-approved protocols for prescribing; post-2026, independent NPs can prescribe non-controlled drugs on their own. Controlled substances (like phentermine) still require physician delegation until full AB 890 implementation.
• Telehealth: No state restrictions on telehealth prescribing; federal rules apply. California has strong telehealth parity laws—insurers must reimburse telehealth visits equally to in-person.

Bottom Line for California: MDs can prescribe freely. NPs are gaining independence but should plan on having an MD medical director for compliance with CPOM and to smooth insurance/pharmacy relationships.

New York: NP Independence After 3,600 Hours

New York allows NPs to practice independently after 3,600 hours of collaborative practice (roughly 2 years full-time). Once you meet that threshold, you can prescribe (including controlled substances) without a physician agreement.

• No Special Weight-Loss Rules: NY doesn’t have Florida-style obesity treatment regulations. Follow standard clinical guidelines (document BMI, informed consent, etc.).
• PMP Requirement: Must check New York’s I-STOP database before prescribing any Schedule II-IV drug (including phentermine).
• Telehealth: NY is telehealth-friendly. No prohibition on controlled substance prescribing via telemedicine (federal waivers allow it). Insurance parity law ensures equal reimbursement for telehealth visits.

Bottom Line for New York: Experienced NPs can practice independently; newer NPs need a collaborative agreement. Psychiatrists have full authority. Both should document thorough evaluations to avoid any claims of negligent prescribing (NY authorities have scrutinized telehealth practices after high-profile cases).

Pennsylvania: Collaborative Practice, Physician Name on Prescriptions

Pennsylvania requires all NPs to have a collaborative agreement with a physician. The agreement must specify which drugs the NP can prescribe; the physician doesn’t need to be on-site but must review charts and be available for consultation. One physician can collaborate with up to 4 NPs.

• Prescription Requirements: PA law requires the CRNP’s prescription blanks to include both the NP’s name/certification number and the collaborating physician’s name. Practically, this means the MD’s name appears on scripts even if the NP is the one managing the patient.
• No Specific Weight-Loss Rules: No state-imposed obesity treatment protocols beyond standard medical practice.
• Telehealth: PA allows telemedicine; no extra restrictions on controlled substance prescribing beyond federal law. Telehealth parity for mental health services is mandated (Act 69), and many insurers cover telehealth broadly.

Bottom Line for Pennsylvania: NPs need an MD collaborator. Psychiatrists can prescribe independently. Both should document properly to meet standard of care.

Illinois: Full Practice Authority After 4,000 Hours

Illinois allows APRNs to achieve Full Practice Authority after ≥4,000 hours of clinical experience and ≥250 hours of continuing education post-licensure. With FPA, you can prescribe independently (including controlled substances, with some caveats for Schedule II in the first year).

• Controlled Substance Prescribing: APRNs with FPA can prescribe Schedule II-V. For Schedule II (not typically used for weight loss), you need 45 hours of pharmacology training and a physician consultation relationship for the first year. Schedule IV (phentermine) is straightforward.
• No Special Weight-Loss Rules: Illinois doesn’t mandate specific obesity treatment protocols at the state level.
• Telehealth & Reimbursement: Strong telehealth parity. Notably, Illinois Medicaid reimburses APRNs at 100% of physician rates—a significant financial incentive. Private insurers generally cover telehealth equivalently to in-person.

Bottom Line for Illinois: If you meet the FPA criteria (most experienced PMHNPs do), you can prescribe weight-loss medications independently. Less experienced NPs need a collaborative agreement. Psychiatrists have full authority. Illinois is one of the most NP-friendly states financially.

Telehealth Prescribing: Federal Waivers, State Conflicts, and Compliance

The pandemic opened telehealth floodgates—but prescribing controlled substances remotely remains legally complex.

Federal Law (Ryan Haight Act & DEA Waivers)

Historically, the Ryan Haight Act required an in-person medical evaluation before prescribing any controlled substance. During COVID-19, the DEA waived this requirement, allowing providers to prescribe controlled meds (including Schedule II-V) via telehealth without a prior in-person visit. That waiver has been extended multiple times—most recently through December 31, 2025 (and likely to be extended further into 2026 given ongoing policy discussions).

This means at the federal level, you can prescribe phentermine (Schedule IV) via telehealth right now—as long as you conduct an appropriate evaluation via audio-video.

State Law Can Override Federal Flexibility

Here’s the trap: the DEA explicitly states that teleprescribing is only legal if it also complies with state law. About 8 states have telemedicine restrictions that effectively ban (or heavily restrict) controlled substance prescribing via telehealth, even though federal waivers are in place. These include:

• Florida: Prohibits controlled substance prescribing via telehealth except for psychiatric disorders, inpatient care, or acute pain. Weight loss doesn’t qualify, so phentermine via telehealth is illegal in FL.
• Alabama: Requires an in-person exam for any controlled substance prescription.
• Idaho, South Carolina: Have similar in-person requirements for controlled drugs.

If you prescribe a controlled appetite suppressant via telehealth to a patient in one of these states, you’re violating state law—even if federal law allows it. The state medical board can discipline you.

For Non-Controlled Weight-Loss Meds (GLP-1s), Telehealth Is Clear

GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are not controlled substances. That means the federal Ryan Haight Act doesn’t apply, and state telehealth restrictions on controlled drugs don’t apply either.

You can prescribe Wegovy, Ozempic, Mounjaro, etc., via telehealth in any state—as long as you:

• Establish a valid patient-provider relationship (usually via live video consultation)
• Conduct an appropriate evaluation (history, review of vitals/BMI, assess contraindications)
• Document your clinical rationale
• Follow any state-specific obesity treatment protocols (like Florida’s 3-month follow-up rule)

Best Practices for Telehealth Prescribing

• Use Live Video for Initial Visits: Some states (and insurers) are skeptical of asynchronous (questionnaire-only) prescribing. A live video exam is the gold standard for establishing rapport, assessing the patient visually, and documenting a thorough evaluation. One Mississippi doctor had his license suspended for prescribing Ozempic via instant messaging without audio/video—don’t be that guy.
• Check State PDMPs: Most states require checking the Prescription Drug Monitoring Program before prescribing controlled substances. Many telehealth EMRs integrate PMP checks.
• Document, Document, Document: Record the patient’s BMI, comorbidities, prior weight-loss attempts, contraindications discussed, informed consent obtained, and monitoring plan. This protects you medically and legally.
• Know Your State’s Rules: Before treating patients in a new state, verify that state’s telehealth and prescribing laws. If you’re working with a telehealth platform, they should handle this compliance legwork—but confirm.

Reimbursement: Can You Actually Get Paid for This?

Adding weight management to your practice only makes sense if it’s financially viable. The good news: reimbursement for obesity treatment is improving rapidly.

Insurance Coverage for GLP-1 Weight-Loss Medications

A few years ago, most insurers excluded weight-loss drugs. That’s changing. Many commercial plans now cover FDA-approved obesity medications (Wegovy, Saxenda) under pharmacy benefits, though usually with:

• Prior Authorization: You’ll need to document BMI ≥30 (or ≥27 with comorbidities like diabetes, hypertension), previous attempts at lifestyle modification (diet/exercise), and sometimes proof the patient is participating in a comprehensive weight management program.
• Quantity Limits: Some insurers (like Blue Cross Blue Shield Texas) impose initial 30-day supply limits for GLP-1s to monitor adherence before approving ongoing refills.
• Step Therapy: A few plans require trying older/cheaper weight-loss meds (like orlistat) before approving a GLP-1.

Expect to spend time on prior authorizations. If you’re on a telehealth platform, they often have staff to handle PA paperwork—ask.

Medicare & Medicaid Game-Changer

Historically, Medicare Part D excluded weight-loss medications by law (the ‘lifestyle drug’ exclusion). That’s ending. In November 2025, the administration announced that Medicare will begin covering anti-obesity medications starting in 2026 as part of negotiated pricing agreements with manufacturers. This opens treatment to millions of seniors and is a massive market shift.

State Medicaid programs vary—some already cover GLP-1s for obesity; others will expand coverage following Medicare’s lead. For providers serving Medicaid populations, this means weight-loss meds will increasingly be reimbursable rather than out-of-pocket.

Billing for the Clinical Visit

For the office visit itself (whether in-person or telehealth), you’ll bill standard E/M codes (99202-99215 for outpatient visits, based on complexity and time). If you’re a psychiatrist doing a medication management visit that includes weight-loss medication adjustment, you use the same codes as any med check.

Some insurers also recognize obesity counseling codes:

• G0447: 15 minutes of face-to-face behavioral counseling for obesity (BMI ≥30), Medicare-covered
• G0473: Group obesity counseling

Psychiatrists might not routinely bill these (they’re often used by dietitians or primary care), but if you’re spending time on nutritional counseling, they’re an option.

Telehealth Parity = Equal Pay

Many states now mandate telehealth payment parity—insurers must reimburse telehealth visits at the same rate as in-person. This includes:

• California: Full parity law for private plans
• New York: Parity effective 2022
• Illinois: Strong telehealth parity and Medicaid covers telehealth broadly
• Texas: Coverage parity (must cover if service is covered in-person), with ongoing push for full payment parity

Medicare extended telehealth flexibilities through 2025+ and pays telehealth visits at office rates (non-facility fee schedule) for psychiatric services. Medicare permanently allows tele-mental health to patients’ homes with no geographic restrictions.

Psychiatrists vs. NPs: Reimbursement Rates

• Psychiatrists (MD/DO): Reimbursed at 100% of physician fee schedule. A typical 15-20 minute med management visit (99213 or 99214) might pay $75-$150 depending on complexity and region.
• PMHNPs: Medicare reimburses NP services at 85% of the physician rate. Some private insurers pay 85-90%; others reimburse NPs at full physician rates. Illinois Medicaid reimburses APRNs at 100% of physician rates, which is unusually generous.

If you’re an NP, you might make slightly less per visit than an MD, but the gap is narrowing—and in volume-based telehealth practices, the difference matters less than your patient throughput and availability.

The Economics of Adding Weight Management

Let’s be realistic about patient acquisition costs and revenue. Many articles claim you can acquire patients for ‘$30-50 per patient’ through DIY marketing. That’s fantasy. Here’s reality:

• SEO: Building a website that ranks for ‘weight loss psychiatrist [your city]’ takes 6-12 months of consistent content, backlinks, and optimization. Most solo providers don’t have the expertise or patience. Realistic timeline to see meaningful patient flow: 12+ months, and you’ll spend $2,000-5,000+ on an agency or consultant during that time.
• Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in wasted clicks, no-shows from cold leads, and ad spend testing.
• Directory Listings (Psychology Today, Zocdoc): Monthly subscription fees ($30-50/month for listings) plus Zocdoc charges $35-100+ per booking. Total monthly cost for directories plus your time managing leads: $200-500+.
• All-In DIY Marketing: If you hire an agency for SEO, run Google Ads, pay for directories, and factor in your staff time handling leads, you’re easily spending $3,000-5,000/month with uncertain ROI. You might acquire 10-20 new patients/month after the ramp-up period, putting your true cost per patient at $150-250+ when you account for failed campaigns and months of investment before results.

Why Platforms Like Klarity Make Economic Sense

Instead of gambling $5,000/month on marketing with no guarantee of results, a platform like Klarity Health uses a pay-per-appointment model. You pay a standard listing fee when a qualified patient books with you—no upfront marketing spend, no monthly subscription, no wasted ad budget.

Key value props:

• Pre-Qualified Patients: Patients are already matched to your specialty, availability, and insurance (or cash-pay if you accept it).
• No Wasted Spend: You only pay when a patient actually shows up. No paying for clicks that don’t convert or leads that ghost.
• Built-In Infrastructure: Telehealth platform, billing support, credentialing assistance—all included. You don’t pay separately for a Zoom alternative or EHR integration.
• Both Insurance and Cash-Pay Flow: The platform handles insurance credentialing and contracts, so you can see insured patients (higher volume, predictable reimbursement) without the usual contracting headaches.
• You Control Your Schedule: Set your availability; only see patients when it fits your life. Take time off without burning a monthly subscription fee.

The economics are simple: instead of spending thousands gambling on marketing, you pay a known fee per patient and keep the appointment revenue. That’s guaranteed ROI versus uncertain marketing spend.

Frequently Asked Questions

Can a psychiatrist legally prescribe Wegovy or Ozempic for weight loss?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all states for FDA-approved weight-loss medications, including GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). The key is ensuring you’re practicing within your competence—consider additional training in obesity medicine if this will be a significant part of your practice.

Do I need special certification to prescribe weight-loss medications?

No legal requirement exists for additional certification beyond your medical license. However, pursuing education in obesity treatment (such as ABOM certification) demonstrates competency and may be necessary to meet the standard of care, especially if prescribing becomes a regular part of your practice. State medical boards expect you to practice within your training and competence.

Can PMHNPs prescribe GLP-1s independently?

It depends on your state. In full-practice-authority states (like Washington, Oregon, Montana, Maryland, and about 20 others), experienced PMHNPs can prescribe weight-loss medications including GLP-1s independently—provided it’s within your competency. In collaborative states (Texas, Florida, Pennsylvania, etc.), you need a physician agreement that explicitly authorizes weight-loss prescribing. Check your state’s NP scope-of-practice laws.

Can I prescribe phentermine via telehealth?

In most states, yes—during the current federal DEA waiver period that extends through at least December 31, 2025. However, some states (notably Florida, Alabama, Idaho) prohibit controlled substance prescribing via telehealth for weight loss. GLP-1 agonists (non-controlled) can be prescribed via telehealth in all states. Always verify your specific state’s telehealth prescribing laws before treating patients remotely.

What if my state requires an in-person exam before prescribing weight-loss drugs?

A few states (like Florida) mandate a comprehensive physical exam before prescribing obesity medications. If you’re practicing via telehealth, you can often meet this requirement through a thorough video consultation plus review of patient-provided vitals (weight, blood pressure) and labs. Some telehealth platforms partner with local labs or health centers to facilitate initial exams where required. Document everything meticulously.

Will insurance cover GLP-1 weight-loss medications?

Increasingly, yes. Many commercial plans now cover FDA-approved obesity medications (Wegovy, Saxenda) with prior authorization. Medicare will begin covering them in 2026. Medicaid coverage varies by state but is expanding. Expect to complete prior authorization paperwork documenting BMI ≥30 (or ≥27 with comorbidities), previous lifestyle interventions, and participation in a comprehensive weight management program.

How much can I earn doing weight-loss medication management?

A typical follow-up visit (15-20 minutes for med management, monitoring side effects, adjusting dose) bills at $75-150 via insurance, depending on your CPT code and region. Psychiatrists are reimbursed at 100% of physician rates; PMHNPs typically 85% from Medicare, though some states (Illinois) pay 100%. If you’re seeing 4-6 patients per hour via telehealth and billing insurance, you can generate $300-600+/hour in revenue. Cash-pay models charge $50-150 per consultation, but limit your market to affluent patients.

Is it ethical for a psychiatrist to treat obesity, or should I refer to primary care?

If you have the training and competency, it’s entirely ethical—especially when obesity and mental health intersect (medication-induced weight gain, binge eating disorder, depression worsening from metabolic issues). Many psychiatrists now see metabolic health as part of holistic psychiatric care. That said, collaboration is wise: communicate with the patient’s PCP, don’t usurp necessary medical workups (rule out endocrine causes, get baseline labs), and refer to specialists (endocrinology, cardiology) when appropriate. Document that your intervention is part of comprehensive care, not isolated cosmetic prescribing.

Ready to Add Weight Management to Your Practice?

Whether you’re an established psychiatrist looking to offer more comprehensive care or a PMHNP building an independent practice, weight-loss medication management represents a legitimate clinical and financial opportunity—if you navigate the regulatory landscape correctly.

The key steps:

1. Get trained: Pursue obesity medicine CME or ABOM certification
2. Verify your state’s rules: Understand NP scope-of-practice, telehealth restrictions, and any state-specific prescribing protocols
3. Set up compliant workflows: Document BMI, obtain informed consent, schedule required follow-ups, check PDMPs for controlled substances
4. Decide on your model: Solo practice with DIY marketing (expensive, slow), or join a telehealth platform that handles patient acquisition, credentialing, and infrastructure

Joining Klarity Health eliminates the biggest barriers: no upfront marketing spend, no months of SEO waiting, no wasted ad budget. You get pre-qualified patients matched to your availability, built-in telehealth infrastructure, and predictable economics—you only pay when you see patients.

Instead of gambling thousands on Google Ads or waiting a year for organic traffic, you can start seeing weight management patients within weeks and keep 100% of the appointment revenue after the platform fee. It’s the smart economic choice for providers who want to grow their practice without the financial risk of traditional marketing.

Explore Klarity’s provider network and see how joining a platform built for psychiatric prescribers can accelerate your practice growth while you focus on what you do best: treating patients.

References and Sources

1. MedicalDirector Co., ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025), https://www.medicaldirectorco.com/collaborative-physician-cost-weight

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting